Related Experiment Video
Updated: May 29, 2026
03:07
Single-Port Robotic-assisted Transaxillary Breast-conserving Surgery: A Prospective, Single-arm, Non-randomized Phase IIa Clinical Trial
Published on: August 19, 2025
Early outcomes data for accelerated partial breast irradiation using balloon brachytherapy
Laurie W Cuttino1, Frank A Vicini
1Department of Radiation Oncology, Virginia Commonwealth University Health System, Richmond, VA, USA.
Expert Review of Anticancer Therapy
|September 21, 2011
Summary
Accelerated partial breast irradiation, a 5-day radiation therapy, shows excellent outcomes for early-stage breast cancer. This targeted treatment offers high local control with minimal toxicity.
Area of Science:
- Oncology
- Radiation Oncology
- Surgical Oncology
Background:
- Accelerated partial breast irradiation (APBI) is an alternative to whole breast irradiation for early-stage breast cancer.
- Traditional whole breast irradiation requires approximately 6 weeks of treatment.
- APBI targets radiation to the tissue surrounding the lumpectomy cavity, reducing treatment time.
Purpose of the Study:
- To evaluate the efficacy and safety of accelerated partial breast irradiation (APBI) in selected early-stage breast cancer patients.
- To assess the role of modern intracavitary brachytherapy techniques in breast cancer management.
Main Methods:
- Balloon brachytherapy, introduced in 2000, is a key technique for APBI.
- Utilizing newer multilumen devices for optimal target coverage.
- Focusing radiation delivery to the lumpectomy cavity and surrounding tissue.
Main Results:
- Excellent outcomes have been demonstrated in carefully selected patient cohorts.
- High rates of local tumor control are achieved with APBI.
- Minimal treatment-related toxicity is observed, including reduced dose to the skin and chest wall.
Conclusions:
- Modern intracavitary brachytherapy, specifically APBI, is a promising radiation therapy option for early-stage breast cancer.
- This approach offers a favorable balance of high local control and low toxicity.
- Advancements in device technology enhance treatment precision and patient safety.
